
    slow accrual
  
['pancreatic cancer']
['gemcitabine']

        Inclusion Criteria:

          1. Histologically or cytologically confirmed adenocarcinoma of the pancreas

          2. Patients is a candidate for gemcitabine chemotherapy (adjuvant, metastatic, locally
             advanced, borderline resectable settings all permitted)

          3. Patients at least 18 years of age

          4. ECOG performance status 0-2

          5. Consent to donate 12 tubes of peripheral blood of 10 mL each

          6. Adequate organ function as defined as -neutrophil count ≥ 1200 -platelets ≥ 75,000
             -hemoglobin ≥ 8.0 -bilirubin ≤ 2.0 -creatinine ≤2.0 or calculated GFR ≥ 30

          7. Ability to understand and willingness to sign a written informed consent document

          8. Prior chemotherapy permitted, as long as 60 days have lapsed since last dose. Prior
             radiation therapy permitted, as long as 28 days lapsed since last treatment.

          9. Patients may receive other concurrent chemotherapy, immunotherapy, or radiotherapy

        Exclusion Criteria:

          1. Patients never been immunized with tetanus toxoid (TT). Patients with a history of
             adverse reaction to tetanus vaccine (with the exception of self-limited fever or local
             tissue reaction

          2. Patients may not be receiving any investigational agents

          3. Pregnant women

          4. Patients with HIV
      